ANIX Anixa Biosciences Inc.

Anixa Biosciences Inc.

Biotechnology: Pharmaceutical Preparations

Health Care

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain viral protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. It has a collaboration agreement with MolGenie GmbH to discover and develop anti-viral drug candidates against COVID-19. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was founded in 1982 and is based in San Jose, California.

IPO Year:

Exchange: NASDAQ

Website: anixa.com

Recent Analyst Ratings for Anixa Biosciences Inc.

Date	Price Target	Rating	Analyst
3/21/2025	$10.00	Buy	Maxim Group
12/23/2022	$8.00	Buy	Chardan Capital Markets

See more ratings

Anixa Biosciences Inc.

Recent Analyst Ratings for Anixa Biosciences Inc.

Anixa Biosciences Inc.

Recent Analyst Ratings for Anixa Biosciences Inc.

Anixa Biosciences Inc. Press Releases

Anixa Biosciences and Moffitt Cancer Center Complete Dosing of Fourth Cohort in Ovarian Cancer CAR-T Clinical Trial; Multiple Patients Surpassing Median Expected Survival

Anixa Biosciences Announces Time Change for Presentation at the H.C. Wainwright 27th Annual Global Investment Conference

Anixa Biosciences to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Anixa Biosciences Receives Notice of Allowance from Chinese National Intellectual Property Administration for Patent Covering Breast Cancer Vaccine Technology

Anixa Biosciences Announces Treatment of Second Patient in Fourth Cohort of Ovarian Cancer CAR-T Clinical Trial

Anixa Biosciences Announces Issuance of Additional U.S. Patent for CAR-T Technology

Anixa Biosciences Announces Dr. Robert Wenham will speak about Immunotherapy in surviving Ovarian Cancer at the 13th Annual Ovarcoming Cancer Conference

Anixa Biosciences Announces Commencement of US FDA Approved IND Transfer to Support Upcoming Phase 2 Breast Cancer Vaccine Trial

Anixa Biosciences Receives Notice of Allowance from Canadian Intellectual Property Office for Patent Covering Breast Cancer Vaccine Technology

Anixa Biosciences Awarded New U.S. Patent Extending Breast Cancer Vaccine IP Protection into 2040s

Anixa Biosciences Inc. Insider Purchases

Director Titterton Lewis H Jr bought $30,800 worth of shares (10,000 units at $3.08), increasing direct ownership by 1% to 953,334 units (SEC Form 4)

Chief Executive Officer Kumar Amit bought $15,800 worth of shares (5,000 units at $3.16), increasing direct ownership by 0.87% to 579,925 units (SEC Form 4)

Director Baskies Arnold M bought $16,950 worth of shares (5,000 units at $3.39), increasing direct ownership by 4% to 125,000 units (SEC Form 4)

Director Titterton Lewis H Jr bought $31,400 worth of shares (10,000 units at $3.14), increasing direct ownership by 1% to 943,334 units (SEC Form 4)

Chief Executive Officer Kumar Amit bought $15,750 worth of shares (5,000 units at $3.15), increasing direct ownership by 0.88% to 574,925 units (SEC Form 4)

Chief Executive Officer Kumar Amit bought $28,500 worth of shares (10,000 units at $2.85), increasing direct ownership by 2% to 569,925 units (SEC Form 4)

Director Baskies Arnold M bought $14,100 worth of shares (5,000 units at $2.82), increasing direct ownership by 4% to 120,000 units (SEC Form 4)

Director Titterton Lewis H Jr bought $8,820 worth of shares (3,000 units at $2.94), increasing direct ownership by 0.32% to 933,334 units (SEC Form 4)

Director Titterton Lewis H Jr bought $6,020 worth of shares (2,000 units at $3.01), increasing direct ownership by 0.22% to 930,334 units (SEC Form 4)

Director Titterton Lewis H Jr bought $15,540 worth of shares (6,000 units at $2.59), increasing direct ownership by 0.65% to 928,334 units (SEC Form 4)

Anixa Biosciences Inc. Insider Trading

Director Titterton Lewis H Jr bought $30,800 worth of shares (10,000 units at $3.08), increasing direct ownership by 1% to 953,334 units (SEC Form 4)

Chief Executive Officer Kumar Amit bought $15,800 worth of shares (5,000 units at $3.16), increasing direct ownership by 0.87% to 579,925 units (SEC Form 4)

Director Baskies Arnold M bought $16,950 worth of shares (5,000 units at $3.39), increasing direct ownership by 4% to 125,000 units (SEC Form 4)

Director Titterton Lewis H Jr bought $31,400 worth of shares (10,000 units at $3.14), increasing direct ownership by 1% to 943,334 units (SEC Form 4)

Chief Executive Officer Kumar Amit bought $15,750 worth of shares (5,000 units at $3.15), increasing direct ownership by 0.88% to 574,925 units (SEC Form 4)

Chief Executive Officer Kumar Amit bought $28,500 worth of shares (10,000 units at $2.85), increasing direct ownership by 2% to 569,925 units (SEC Form 4)

Director Baskies Arnold M bought $14,100 worth of shares (5,000 units at $2.82), increasing direct ownership by 4% to 120,000 units (SEC Form 4)

Director Titterton Lewis H Jr bought $8,820 worth of shares (3,000 units at $2.94), increasing direct ownership by 0.32% to 933,334 units (SEC Form 4)

Director Titterton Lewis H Jr bought $6,020 worth of shares (2,000 units at $3.01), increasing direct ownership by 0.22% to 930,334 units (SEC Form 4)

Director Titterton Lewis H Jr bought $15,540 worth of shares (6,000 units at $2.59), increasing direct ownership by 0.65% to 928,334 units (SEC Form 4)

Anixa Biosciences Inc. Analyst Ratings

Maxim Group initiated coverage on Anixa Biosciences with a new price target

Chardan Capital Markets initiated coverage on Anixa Biosciences with a new price target

HC Wainwright & Co. initiated coverage on Anixa Biosciences with a new price target

Anixa Biosciences Inc. SEC Filings

SEC Form S-3 filed by Anixa Biosciences Inc.

SEC Form 10-Q filed by Anixa Biosciences Inc.

SEC Form 10-Q filed by Anixa Biosciences Inc.

Anixa Biosciences Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits

SEC Form 10-Q filed by Anixa Biosciences Inc.

SEC Form DEF 14A filed by Anixa Biosciences Inc.

SEC Form S-8 filed by Anixa Biosciences Inc.

SEC Form 10-K filed by Anixa Biosciences Inc.

Amendment: SEC Form SCHEDULE 13D/A filed by Anixa Biosciences Inc.

Anixa Biosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

Anixa Biosciences Inc. Financials

Anixa Biosciences and Cleveland Clinic Present Positive New Data from Phase 1 Study of Breast Cancer Vaccine

Anixa Biosciences to Host Conference Call This Evening to Discuss Positive New Data from Ongoing Phase 1 Study of Breast Cancer Vaccine

Anixa Biosciences Inc. Leadership Updates

Anixa Biosciences Appoints Suyasha Gupta as Senior Director of Clinical Development

Anixa Biosciences CEO Featured on "Target: Cancer Podcast" by Oncologist Dr. Sanjay Juneja

Anixa Biosciences Welcomes Celebrity Oncologist Dr. Sanjay Juneja to its Cancer Business Advisory Board

Anixa Biosciences Appoints Dr. Pamela Garzone As Chief Development Officer

Anixa Biosciences Inc. Large Ownership Changes

SEC Form SC 13D filed by Anixa Biosciences Inc.

SEC Form SC 13D/A filed by Anixa Biosciences Inc. (Amendment)

SEC Form SC 13D/A filed by Anixa Biosciences, Inc. (Amendment)

SEC Form SC 13D/A filed by Anixa Biosciences, Inc. (Amendment)

SEC Form SC 13D/A filed